GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curocell Inc (XKRX:372320) » Definitions » Total Long-Term Assets

Curocell (XKRX:372320) Total Long-Term Assets : ₩62,211.97 Mil (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Curocell Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Curocell's Total Long-Term Assets for the quarter that ended in Jun. 2023 was ₩62,211.97 Mil.


Curocell Total Long-Term Assets Historical Data

The historical data trend for Curocell's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curocell Total Long-Term Assets Chart

Curocell Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Long-Term Assets
7,448.11 10,026.99 18,002.71 46,590.39 62,182.51

Curocell Semi-Annual Data
Jun22 Dec22 Jun23 Dec23
Total Long-Term Assets - 46,590.39 62,211.97 62,182.51

Curocell Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.


Curocell Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of Curocell's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Curocell (XKRX:372320) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
11, Gukjegwahak 16-ro, Yuseong-gu, Daejeon, KOR, 34002
Curocell Inc is engaged in medical and pharmaceutical research and development. The company is into development of CAR-T treatments that enhance the natural function of immune cells to eliminate cancer cells through genetic manipulation of human immune cells.

Curocell (XKRX:372320) Headlines

No Headlines